Literature DB >> 6136655

Changes in malaria incidence after mass drug administration in Nicaragua.

R M Garfield, S H Vermund.   

Abstract

Mass drug administration (MDA) in 1981 reduced the incidence rates of both Plasmodium vivax and P falciparum infection in Nicaragua. Impact on P vivax cases lasted for four months and on P falciparum for seven. Subtherapeutic primaquine doses, the shorter extrinsic cycle of P vivax in the insect vector, and the timing of MDA at a high-transmission period of the year may explain the limited effects of the campaign. Positive results of the anti-malaria campaign included improvements in case-finding and routine surveillance, the apparent prevention of at least 9200 malaria cases, the training of some 70 000 antimalaria volunteers, and the participation of about 70% of the population in anti-malarial activities.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6136655     DOI: 10.1016/s0140-6736(83)90523-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  24 in total

1.  Health services reforms in revolutionary Nicaragua.

Authors:  R M Garfield; E Taboada
Journal:  Am J Public Health       Date:  1984-10       Impact factor: 9.308

Review 2.  Mass drug administration for malaria.

Authors:  Eugenie Poirot; Jacek Skarbinski; David Sinclair; S Patrick Kachur; Laurence Slutsker; Jimee Hwang
Journal:  Cochrane Database Syst Rev       Date:  2013-12-09

Review 3.  Mass drug administration for malaria.

Authors:  Monica P Shah; Jimee Hwang; Leslie Choi; Kim A Lindblade; S Patrick Kachur; Meghna Desai
Journal:  Cochrane Database Syst Rev       Date:  2021-09-29

4.  The relative impact of interventions on sympatric Plasmodium vivax and Plasmodium falciparum malaria: A systematic review.

Authors:  Melanie Loeffel; Amanda Ross
Journal:  PLoS Negl Trop Dis       Date:  2022-06-29

5.  Why do child mortality rates fall? An analysis of the Nicaraguan experience.

Authors:  P Sandiford; P Morales; A Gorter; E Coyle; G D Smith
Journal:  Am J Public Health       Date:  1991-01       Impact factor: 9.308

Review 6.  Operational strategies to achieve and maintain malaria elimination.

Authors:  Bruno Moonen; Justin M Cohen; Robert W Snow; Laurence Slutsker; Chris Drakeley; David L Smith; Rabindra R Abeyasinghe; Mario Henry Rodriguez; Rajendra Maharaj; Marcel Tanner; Geoffrey Targett
Journal:  Lancet       Date:  2010-10-28       Impact factor: 79.321

7.  A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania.

Authors:  Seif A Shekalaghe; Chris Drakeley; Sven van den Bosch; Roel ter Braak; Wouter van den Bijllaardt; Charles Mwanziva; Salimu Semvua; Alutu Masokoto; Frank Mosha; Karina Teelen; Rob Hermsen; Lucy Okell; Roly Gosling; Robert Sauerwein; Teun Bousema
Journal:  Malar J       Date:  2011-08-24       Impact factor: 2.979

8.  Impact of Community-Based Mass Testing and Treatment on Malaria Infection Prevalence in a High-Transmission Area of Western Kenya: A Cluster Randomized Controlled Trial.

Authors:  Aaron M Samuels; Nobert Awino Odero; Wycliffe Odongo; Kephas Otieno; Vincent Were; Ya Ping Shi; Tony Sang; John Williamson; Ryan Wiegand; Mary J Hamel; S Patrick Kachur; Laurence Slutsker; Kim A Lindblade; Simon K Kariuki; Meghna R Desai
Journal:  Clin Infect Dis       Date:  2021-06-01       Impact factor: 20.999

Review 9.  Review of mass drug administration for malaria and its operational challenges.

Authors:  Gretchen Newby; Jimee Hwang; Kadiatou Koita; Ingrid Chen; Brian Greenwood; Lorenz von Seidlein; G Dennis Shanks; Laurence Slutsker; S Patrick Kachur; Jennifer Wegbreit; Matthew M Ippolito; Eugenie Poirot; Roly Gosling
Journal:  Am J Trop Med Hyg       Date:  2015-05-26       Impact factor: 2.345

10.  Alert threshold algorithms and malaria epidemic detection.

Authors:  Hailay Desta Teklehaimanot; Joel Schwatrz; Awash Teklehaimanot; Marc Lipsitch
Journal:  Emerg Infect Dis       Date:  2004-07       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.